[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urogenital-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urogenital-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,73,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100433365","a-multi-center-natural-history-of-urothelial-cancer-and-rare-genitourinary-tract-malignancies-100433365",false,"NCT04923178","A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies","* INCLUSION CRITERIA:\n* Participants must have histologically or cytologically confirmed urothelial or rare genitourinary cancer including but not limited to the following: small cell carcinoma of the bladder; adenocarcinoma of the bladder; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; any testicular cancer, sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, testicular Sertoli or Leydig cell tumors. Any genitourinary cancer can be included at the principal investigator's discretion.\n* Age \\>=18 years.\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-None","ALL","18 Years",{"count":18,"type":19},1100,"ESTIMATED","OBSERVATIONAL","Background:\n\nTumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare. Some GU tumors are so rare that they are not included in treatment studies or tissue banks. This makes it hard for researchers to determine standards of care. Researchers want to learn more about common and rare GU tumors.\n\nObjective:\n\nTo learn more about urinary tract cancers.\n\nEligibility:\n\nPeople ages 18 and older with urinary tract or GU cancer such as bladder, kidney, testicular, prostate, penis, or neuroendocrine cancer.\n\nDesign:\n\nParticipants will be screened with questions about their medical history. Their medical records will be reviewed.\n\nParticipants will have a physical exam. They will give blood and urine samples. They will complete a survey about their family cancer history. Clinical photographs will be taken to document skin lesions.\n\nParticipants may have imaging scans of their chest, abdomen, and pelvis. They may have a contrast agent injected into their arm.\n\nParticipants will get recommendations about how to best manage and treat their cancer. They can ask as many questions as they would like.\n\nParticipants will provide existing tumor samples if available. They may have optional tumor biopsies up to twice a year. For needle biopsies, the biopsy area will be numbed and they will get a sedative. A needle will be inserted through their skin to collect a tumor sample. For skin biopsies, their skin will be numbed. A small circle of skin will be removed.\n\nSome blood and tumor samples may be used for genetic tests.\n\nParticipants will have frequent follow-up visits. If they cannot visit NIH, their home doctor will be contacted. They will be followed on this study for life....",[23,24,25,26,27],"Urothelial Cancer","Bladder Cancer","Genitourinary Cancer","Urogenital Neoplasms","Urogenital Cancer",[29,30,31,32,33,34],"bladder\u002Furachal adenocarcinoma","renal tumors","penile cancers","small cell neuroendocrine carcinoma of the prostate","Renal Cell Carcinoma","Natural History","RECRUITING","2026-06-04",{"date":38,"type":39},"2026-06-05","ACTUAL",{"date":41,"type":39},"2022-10-24",{"date":43,"type":19},"2042-12-01",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100380606","phase-1-bintrafusp-alfa-m7824-and-pds01adc-alone-and-in-combination-with-stereotactic-body-radiation-therapy-sbrt-in-adults-with-metastatic-non-prostate-genitourinary-malignancies-100380606","NCT04235777","Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","A Phase I Study of Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","* INCLUSION CRITERIA:\n* Participants must have histologically or cytologically confirmed diagnosis of a metastatic non-prostate genitourinary tumor.\n* Participants must have metastatic disease defined as new or progressive lesions on cross-sectional imaging. Radiological evaluation should occur within 21 days prior to enrollment.\n* Participants must have evaluable or measurable disease, per RECIST 1.1.\n* Participants in Arms 2 and 3 must have at least one site of disease that is amenable to irradiation (irradiation of up to 4 different sites is permitted)\n* Participants must have at least one measurable site of disease (according to RECIST criteria) that will not be irradiated.\n* Participants may have been previously treated with cytotoxic chemotherapy regimen or targeted agent. Participants may have received any number of prior cytotoxic agents.\n* Participants may have been previously treated with radiation therapy. However, re-irradiation of a previously irradiated site is not permitted unless explicitly discussed with protocol PI and treating radiation oncologist.\n* Participants may have had prior immunomodulating therapy including therapy with a checkpoint inhibitor but excluding prior treatment with M7824 and\u002For PDS01ADC.\n* Participants with locally advanced\u002Fmetastatic clear cell renal cell cancer must have previously received, refused or been ineligible for either axitinib plus pembrolizumab, cabozantinib plus nivolumab, levantinib plus pembrolizumab, axitinib plus avelumab, nivolumab plus ipilumumab, cabozantinib, pazopanib, sunitinib or axitinib.\n* Participants with locally advanced or mestastatic germ cell tumors must have received, refused or been ineligible for prior bleomycin plus etoposide plus cisplatin, etoposide plus cisplatin, etoposide plus ifosfamide plus cisplatin, vinblastine plus ifosfamide plus cisplatin, paclitaxel plus ifosfamide plus cisplatin or autologous hematopoietic cell transplantation.\n* Participants with locally advanced\u002Fmetastatic urothelial cancer must have previously received, refused or been ineligible for platinum chemotherapy and\u002For single agent PD-1\u002FPD-L1 inhibitor.\n* Pre-treatment tissue availability for PD-L1 expression testing is mandatory for enrollment. If tissue is determined to be of insufficient\u002Funsuitable quality\u002Fquantity, a pre-treatment biopsy prior to initiation of study therapy will be required.\n* Male and female participants who are at least 18 years of age on the day of signing the informed consent will be enrolled in the study.\n* ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%)\n* Participants must have adequate organ and marrow function as defined below:\n\n  * leukocytes greater than or equal to 2500mcL\n  * absolute neutrophil count greater than or equal to 1500\u002FmcL\n  * platelets greater than or equal to 100,000\u002FmcL\n  * Aspartate Aminotransferase (AST)\u002F Alanine Aminotransferase (ALT) less than or equal to 1.5 X institutional upper limit of normal (ULN)\n  * Hemoglobin (Hgb) greater than or equal to 9g\u002FdL (Packed red blood cells (pRBC) transfusions are allowed to achieve acceptable Hgb)\n* Participants may have mild to moderate hepatic impairment with total bilirubin less than or equal to 3.0 x ULN.\n* For participants with liver involvement in their tumor, we allow the following: AST less than or equal to 5.0 x ULN, ALT less than or equal to 5.0 x ULN, and bilirubin less than or equal to 3.0 x ULN.\n* Calculated Creatinine clearance greater than or equal to 20 mL\u002Fmin (using either CKD-EPY equation)\n* The effects of M7824 and\u002For PDS01ADC on the developing human fetus are unknown. For this reason, individuals of child-bearing potential (IOCBP) and individuals able to father a child must agree to use strict and effective contraception during treatment and after the last dose of M7824 administration - at least 65 days after for IOCBP and 125 days after for individuals able to father a child. Should IOCBPs become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately.\n* Human Immunoodeficiency Virus (HIV)-positive participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are greater than 350 cells\u002Fmm3 and viral load is undetectable.\n* Participants with previously treated brain or central nervous system (CNS) metastases are eligible provided that the participant has recovered from any acute effects of radiotherapy and is not requiring steroids, and any whole brain radiation therapy was completed at least 2 weeks prior to M7824 administration, or any stereotactic radiosurgery was completed at least 2 weeks prior to M7824 administration.\n* Hepatitis B Virus (HBV) positive participants are eligible-they must have been treated and on a stable dose of antivirals \\[eg, entecavir, tenofovir, or lamivudine; (adefovir or interferon are not allowed)\\] at study entry and with planned monitoring and management according to appropriate labeling guidance.\n* Hepatitis B Virus (HCV) positive participants are eligible if participants are on active HCV therapy at study entry and must be on a stable dose without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling guidance.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to M7824 and\u002For PDS01ADC investigational agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. Participants with a history of bleeding diathesis or recent clinically significant bleeding events considered by the Investigator as high risk for investigational drug treatment are also excluded with the exception of hematuria.\n* Participants unwilling to accept blood products as medically indicated\n* Pregnant individuals are excluded from this study because M7824 and\u002For PDS01ADC are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M7824 and\u002For PDS01ADC, nursing should be discontinued if the nursing individual is treated with these agents.\n* Participants with any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required treatment with either systemic corticosteroids (\\> 10 mg daily prednisone equivalent) or immunosuppressive medications. Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Participants with inflammatory bowel disease that have been in remission for at least 5 years whether or not they are currently on immunosuppressive therapy provided that they are not on systemic corticosteroids (\\> 10mg daily prednisone equivalent) are eligible.\n* Participants with any active or recent history of inflammatory bowel disease, active lupus or scleroderma or other medical conditions (i.e., pneumonits with planned SBRT to lung lesion) or genetic radiosensitivity syndromes will be excluded from the study unless deemed eligible by Principal Investigator because these diseases make the participant unsafe or ineligible for radiation therapy with SBRT.\n* Participants with a \"currently active\" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ or incidental organ-confined prostate cancer found on cystoprostatectomy (provided that the following criteria are met: Stage T2N0M0 or lower; Gleason score \\\u003C= 3+4, Prostate-Specific Antigen (PSA) undetectable). Participants are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for \\>= 2 years and currently do not require systemic therapy.\n* Participants having tumor lesion(s) in the liver or chest which are 10 cm or larger.","120 Years",{"count":57,"type":19},100,"INTERVENTIONAL",[60],"PHASE1","Background:\n\nGenitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer. The drug PDS01ADC triggers the immune system to fight cancer. Researchers want to learn if these drugs can help fight these cancers when given with and without Stereotactic Body Radiation Therapy (SBRT) radiation.\n\nObjective:\n\nTo learn if M7824 and PDS01ADC, with or without SBRT, can help the immune system to fight cancer better.\n\nEligibility:\n\nPeople 18 and older with cancer that started in the bladder, kidneys, or other genitourinary organs (but not the prostate) and has spread to other parts of the body.\n\nDesign:\n\nParticipants will be screened with:\n\nmedical history\n\nphysical exam\n\nability to do their normal activities\n\nblood tests\n\nurine tests\n\nelectrocardiogram\n\nbody scans.\n\nParticipants will give a tumor sample or have a tumor biopsy.\n\nScreening tests will be repeated during the study.\n\nParticipants will get PDS01ADC . It is injected under the skin every 4 weeks. They will also get M7824 through an intravenous (IV) infusion every 2 weeks. For this, a small plastic tube is put into a vein in the arm. They will get these drugs in 28-day cycles until they leave the study. They may have SBRT.\n\nParticipants will give tissue and saliva samples.\n\nParticipants will have a follow-up visit 30 days after treatment ends. Then they will get phone calls or emails every 12 weeks indefinitely.",[23,24,25,26,27],[64,33,65,66],"Immunocytokine","Urothelial carcinoma","Immune Therapy",{"date":38,"type":39},{"date":69,"type":39},"2020-07-13",{"date":71,"type":19},"2027-12-01",{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":58,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":47},"100410430","phase-2-neoadjuvant-immune-checkpoint-inhibitor-treatment-in-urothelial-cancer-100410430","NCT04624399","Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer","Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer","ABACUS-2","Inclusion Criteria:\n\nCohort-Specific Inclusion Criteria • Bladder cohort: Histopathologically confirmed carcinoma of the urothelium (T1 high grade -T4a) in the bladder with mixed or rare histological subtypes such as squamous cell or adenocarcinoma. Patients with mixed histologies are required to have a dominant non- transitional cell pattern.\n\n• UTUC cohort:\n\nHistopathologically confirmed,high grade or high risk upper urinary tract urothelial carcinoma (renal pelvis and ureter). This cohort includes all patients with upper tract malignancy who in the opinion of the investigators qualify for radical surgery (nephroureterectomy or distal ureter resection). Urothelial carcinoma of the upper urinary tract qualifies as high-risk disease if any of the below factors are present:\n\n* Hydronephrosis\n* Tumour size \\>2cm on cross sectional imaging\n* High grade cytology\n* High grade biopsy\n* Multifocal disease\n* Variant histology\n* Previous radical cystectomy for urothelial cancer of the bladder\n\nAll patients undergoing radical surgery with curative intent in the opinion of the investigator are eligible. Radical surgical interventions include nephroureterectomy or distal ureteral resection.\n\nGeneral inclusion criteria:\n\n1. Willing and able to provide written informed consent\n2. Ability to comply with the protocol\n3. Age ≥ 18 years\n4. Residual disease after TURBT or URS (surgical opinion, endoscopy or radiological presence).\n5. Fit and planned for radical surgery with curative intent in the opinion of the investigator (according to local guidelines).\n6. N0 or M0 disease CT or MRI (within 4 weeks of registration)\n7. Representative formalin-fixed paraffin embedded (FFPE) tumour samples with an associated pathology report that are determined to be available and sufficient for central testing.\n8. Patients who refuse neoadjuvant cisplatin-based chemotherapy or in whom neoadjuvant cisplatin-based therapy is not appropriate.\n9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n10. Negative pregnancy test within 2 weeks of Day 1 Cycle 1 for female patients of childbearing potential.\n11. For female patients of childbearing potential to use a highly effecting form(s) of contraception (i.e. one that results in a low failure rate \\[\\\u003C1% per year\\] when used consistently and correctly) and to continue its use for 90 days after the last dose of atezolizumab.\n12. Adequate hematologic and end-organ function within 4 weeks prior to the first study treatment defined by the following:\n\n    1. ANC ≥ 1500 cells\u002FμL (without granulocyte colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1)\n    2. WBC counts \\> 2500\u002FμL\n    3. Lymphocyte count ≥ 500\u002FμL\n    4. Platelet count ≥ 100,000\u002FμL (without transfusion within 2 weeks prior to Cycle 1, Day 1)\n    5. Haemoglobin ≥ 9.0 g\u002FdL (patients may be transfused or receive erythropoietic treatment to meet this criterion).\n    6. AST or ALT,and alkaline phosphatase ≤ 2.5 times the institutional upper limit of normal (ULN) (patients with known Gilbert disease who have serum bilirubin level ≤ 3 × the institutional ULN may be enrolled).\n    7. INR and aPTT ≤ 1.5 × the institutional ULN. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.\n    8. Calculated creatinine clearance ≥ 20 mL\u002Fmin (Cockcroft-Gault formula)\n\nExclusion Criteria:\n\n1. Pregnant and lactating female patients.\n2. Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.\n3. Previously intravenous chemotherapy for urothelial cancer.\n4. Patients with prior allogeneic stem cell or solid organ transplantation.\n5. Prior treatment with CD137 agonists,anti-CTLA-4,anti-programmed death-1 (PD-1),or anti-PD-L1 therapeutic antibody or pathway-targeting agents.\n6. Patients must not have had oral or IV steroids for 14 days prior to study entry. The use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids (i.e.,for adrenal insufficiency), and mineralocorticoids (e.g. fludrocortisone) is allowed.\n7. Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to enrolment (Patients receiving prophylactic antibiotics (e.g.,for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible).\n8. Administration of a live,attenuated vaccine within 4 weeks prior to enrolment or anticipation that such a live,attenuated vaccine will be required during the study.\n9. Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin \\[IL\\]-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrolment.\n10. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to enrolment.\n11. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).\n12. Malignancies other than UC within 5 years prior to Cycle 1,Day 1,with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (Gleason score ≤ 3 + 4 and PSA \\\u003C 10 ng\u002FmL undergoing active surveillance and treatment naive).\n13. Severe infections within 4 weeks prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteraemia,or severe pneumonia.\n14. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to enrolment, unstable arrhythmias, or unstable angina.\n15. History of idiopathic pulmonary fibrosis (including pneumonitis),drug-induced pneumonitis, organizing pneumonia (i.e.,bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan (History of radiation pneumonitis in the radiation field (fibrosis) is permitted).\n16. Patients with uncontrolled Type 1 diabetes mellitus. Patients with Type 1 diabetes controlled on a stable insulin regimen are eligible.\n17. Patients with active hepatitis infection (defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen \\[anti-HBc\\] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n18. Positive test for HIV\n19. Patients with active tuberculosis\n20. History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug.\n21. Uncontrolled hypercalcemia (\\> 1.5 mmol\u002FL ionized calcium or Ca \\> 12 mg\u002FdL or corrected serum calcium \\> the institutional ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab. Patients who are receiving bisphosphonate therapy or denosumab specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible. Patients who are receiving denosumab prior to enrollment must be willing and eligible to receive a bisphosphonate instead while on study.\n22. History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n23. Patients with a history of autoimmune-related hypothyroidism, unless on a stable dose of thyroid-replacement hormone.\n24. History of severe allergic, anaphylactic,or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n25. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation","99 Years",{"count":83,"type":19},58,[85],"PHASE2","This study is being carried out to see if the drug atezolizumab can reduce the size of tumours in patients with types of urothelial cancer before surgery. Atezolizumab is designed to stop a protein called PD-L1 (programmed death-ligand 1) being expressed on the cancer, allowing the immune system to recognise the tumour cells as foreign bodies and attack them. Atezolizumab has been shown to have activity in urothelial cancer which has spread.\n\nThere two cohorts for this trial. One cohort will investigate the most common histological type of urothelial cancer (transitional cell carcinoma) outside the bladder, for example in the upper urinary tract. The other cohort will investigate rarer histological subtypes (such as such as squamous cell or adenocarcinoma) of urothelial cancer throughout the entire urinary system.\n\nThis study will be recruiting patients from hospitals in the UK, France and Spain. If a patient is eligible for the study and decides to take part, they will receive up to two 3-weekly cycles of atezolizumab. 4-8 weeks after being enrolled, the patient will have an operation to remove the bladder (cystectomy) or the kidney, ureter and part of the bladder (nephroureterectomy or distal ureteral resection) as per normal practice. Following surgery, they will attend three hospital visits (4,12 and 24 weeks after surgery) and their disease progress\u002Fsurvival will be followed over the next 2 years. The clinical team will compare the patient's tumour tissue samples,scan results and blood results from before and after treatment with atezolizumab in order to see how well the drug works and if it is safe. Many of the procedures involved in this study are offered as standard care and participation in this trial will not delay surgery.",[27],"2025-11-17",{"date":90,"type":39},"2025-11-18",{"date":92,"type":39},"2021-06-17",{"date":94,"type":19},"2026-05-30",{"name":96,"class":97},"Queen Mary University of London","OTHER",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":47},"100462334","lymphoedema-and-nocturianocturnal-polyuria-after-pelvic-lnd-for-urogenital-cancer-100462334","NCT05300308","Lymphoedema and Nocturia\u002FNocturnal Polyuria After Pelvic LND for Urogenital Cancer","Lymphoedema and Nocturia\u002F Nocturnal Polyuria After Pelvic Lymph Node Dissection (LND): Prospective Observational Study","UroLymph","Inclusion Criteria:\n\n* Non-metastatic urogenital cancer (i.e. prostate cancer or bladder cancer)\n* Planned transperitoneal pelvic lymph node dissection or salvage lymph node dissection\n* Salvage lymph node dissection\n* Before inclusion, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Radiological evidence of metastatic disease based on pelvic CT\u002FMRI and bone scan\n* Clinical signs of chronic venous insufficiency (CEAP C3-C6)\n* History of lymph node dissection\u002F radiotherapy at the level of the pelvis or groin",{"count":107,"type":19},150,"After the treatment of urogenital cancer, a person may develop lymphoedema of the leg(s) and\u002F or midline region. Clinical symptoms include abnormal tissue swelling, sensation of limb heaviness, erythema, pain, and impaired limb function. Lymphoedema can have a negative impact on quality of life (QoL) and the impact of lymphoedema on the cancer treatment decision making process is underestimated. A limited number of studies have evaluated the incidence rate of midline and leg lymphoedema after surgery for urogenital cancers and have investigated the prognostic variables. In addition, to the researchers knowledge, no evidence exists regarding which (combination of) clinical measuring methods are most sensitive to detect early lymphoedema at the lower limbs after the treatment of urogenital cancer. Therefore, in this prospective observational study, the epidemiology (i.e. incidence\u002F prevalence rate and prognostic variables) and the detection methods of lower limb lymphoedema after pelvic lymph node dissection for urogenital cancer will be investigated.\n\nAdditionally, the epidemiology of nocturia and nocturnal polyuria will be studied (since this information is also missing in literature).",[27,110,111,112],"Lower Limb Lymphedema","Nocturia","Nocturnal Polyuria","2025-07-08",{"date":115,"type":39},"2025-07-11",{"date":117,"type":39},"2022-01-21",{"date":119,"type":19},"2026-11",{"name":121,"class":97},"Universitaire Ziekenhuizen KU Leuven"]